hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06368466 id: CLS-016A briefTitle: A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-08-30 date: 2024-09-01 date: 2024-04-16 date: 2024-04-16 name: bioLytical Laboratories class: INDUSTRY name: St Vincent's Hospital Melbourne briefSummary: A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and EDTA venipuncture whole blood are collected by a healthcare professional. The collected samples of capillary and EDTA whole blood are tested on iStatis and EDTA whole blood sample will be processed to obtain serum and plasma samples to be tested on the iStatis. An aliquot of the collected serum sample will be shipped to the central laboratory for confirmatory testing. The results from iStatis HBsAg Test results will not be used for patient management decisions. conditions: Hepatitis B conditions: Hepatitis B Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 350 type: ESTIMATED name: iStatis HBsAg Test measure: Performance measure: Sensitivity and Specificity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Vincent's Hospital, Melbourne city: Melbourne state: Fitzroy Victoria zip: 3065 country: Australia name: Alex Thompson role: CONTACT lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06368453 id: CLS-003 briefTitle: A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-05-01 date: 2024-04-16 date: 2024-04-16 name: bioLytical Laboratories class: INDUSTRY briefSummary: The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing.
To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test. conditions: Human Immunodeficiency Virus I Infection conditions: Human Immunodeficiency Virus II Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: SINGLE whoMasked: CARE_PROVIDER count: 1700 type: ESTIMATED name: INSTI® HIV Self-Test measure: Clinical sensitivity and specificity of the INSTI® HIV Self-Test measure: The INSTI® HIV Self-Test usability and result interpretation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06368427 id: D5980R00100 briefTitle: Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD acronym: COnCORD overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-09-30 date: 2025-09-30 date: 2024-04-16 date: 2024-04-16 name: AstraZeneca class: INDUSTRY briefSummary: The purpose of this study is to describe patients' clinical and self-reported outcomes of treatment with budesonide / glycopyrronium / formoterol Metered dose inhaler (BGF MDI) in Romania in real-life setting, up to 6 month of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks (3 months) of treatment with no pre-defined hypothesis. conditions: Chronic Obstructive Pulmonary Disease (COPD) studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 250 type: ESTIMATED name: budesonide / glycopyrronium / formoterol measure: Change from baseline to 12 weeks (3 months) in the COPD Assessment Test (CAT) score measure: Change from baseline to 6 months in the CAT score measure: Treatment Satisfaction Questionnaire for Medication (TSQM) scores after 12 weeks and 6 months of treatment measure: Percent responders of the CAT [MID=2] after 12 weeks of treatment measure: Proportion of days covered (PDC) Time to discontinuation Reasons for treatment discontinuation measure: Drivers for initiation or switch to BGF MDI via physician questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06368414 id: KCMLWP-2021-04 briefTitle: A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia acronym: AsterA overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2028-08-31 date: 2028-08-31 date: 2024-04-16 date: 2024-04-16 name: Korean Society of Hematology class: NETWORK briefSummary: To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI conditions: Chronic Myeloid Leukemia, Chronic Phase studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 69 type: ESTIMATED name: Asciminib measure: MR3.0 or less by 1 year sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-03-21 uploadDate: 2024-04-11T22:40 filename: Prot_000.pdf size: 903002 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-03-21 uploadDate: 2024-04-11T22:40 filename: Prot_001.pdf size: 903226 hasResults: False
nctId: NCT06368401 id: TP_01428 briefTitle: A First in Human Study for the Versa Device for Tricuspid Regurgitation overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2025-12-31 date: 2024-04-16 date: 2024-04-16 name: Versa Vascular, Inc class: INDUSTRY briefSummary: This study is prospective, non-randomized, single-arm,first in human study to evaluate the safety and feasibility of the Versa Vascular System for intervention in adults with severe tricuspid regurgitation who are not surgical candidates. conditions: Tricuspid Regurgitation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 10 type: ESTIMATED name: Versa Implant measure: Acute Procedural Success measure: Incidence of major adverse events (MAE) measure: Tricuspid Regurgitation Severity Change sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Auckland City Hospital city: Auckland country: New Zealand name: Mark Webster, MD role: CONTACT lat: -36.84853 lon: 174.76349 hasResults: False
nctId: NCT06368388 id: S64854 briefTitle: Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force acronym: PHAGEFORCE overallStatus: RECRUITING date: 2021-06-01 date: 2024-12-01 date: 2025-06-01 date: 2024-04-16 date: 2024-04-16 name: Universitaire Ziekenhuizen KU Leuven class: OTHER name: KU Leuven briefSummary: PHAGEFORCE is a prospective, observational registry study. The University Hospitals Leuven has approved the application of phage therapy as standard-of-care only in patients for whom no curative treatment alternatives (antibiotic and/or surgical) are available ('last-resort cases'). A multidisciplinary phage task force, referred to as the Coordination group for Bacteriophage therapy Leuven (CBL) was set up. The CBL screens patients with difficult-to-treat infections, evaluates who could benefit from phage therapy and sets up the treatment protocol. With this study, the CBL aims to gain insight in the safety and efficacy of phage therapy by integrating and optimizing phage therapy in five distinct medical disciplines (with distinct routes of administration), facilitating long-term follow-up of patients. Furthermore, this study will gain insight in the biodistribution and exact mechanisms of action of phage therapy and thus be able to provide standardized guidelines for each patient population and route of administration. conditions: Musculoskeletal Infection conditions: Chronic Rhinosinusitis (Diagnosis) conditions: Sepsis conditions: Pulmonary Infection conditions: Hidradenitis Suppurativa studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Prospective data collection name: Prospective data collection measure: Disease free period measure: Bacterial eradication measure: PROMIS global health (patient-reported outcome measurement information system) measure: PROMIS (patient-reported outcome measurement information system) physical function measure: PROMIS (patient-reported outcome measurement information system) pain interference measure: Sino-nasal outcome test (SNOT)-22 measure: Visual Analogue Scale (VAS) score measure: Cystic fibrosis questionnaire (CF-Q-R) measure: Dermatology Life Quality Index (DLQI) measure: Hidradenitis Suppurativa Quality of Life (HiSQoL) measure: Rate of exacerbations measure: Abscess and inflammatory nodule (AN) count with Hidradenitis suppurativa Clinical Response (HiSCR) measure: Lund-Mackay CT score measure: Lund Kennedy endoscopy score measure: Modified Davos score sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Leuven status: RECRUITING city: Leuven zip: 3000 country: Belgium name: Jolien Onsea, PhD role: CONTACT phone: 003216342041 email: jolien.onsea@uzleuven.be name: Willem-Jan Metsemakers, MD, PhD role: CONTACT phone: 003216344277 email: willem-jan.metsemakers@uzleuven.be name: Willem-Jan Metsemakers, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 50.87959 lon: 4.70093 hasResults: False
nctId: NCT06368375 id: PRPF31-3102022BO2 briefTitle: Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa overallStatus: COMPLETED date: 2023-01-01 date: 2023-06-30 date: 2023-06-30 date: 2024-04-16 date: 2024-04-16 name: University Hospital Tuebingen class: OTHER briefSummary: Retrospective chart review study to elucidate the genotype and phenotype of patients with PRPF31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s) conditions: Retinitis Pigmentosa studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 87 type: ACTUAL measure: Best Corrected Visual Acuity (BCVA) measure: Visual Field (VF) measure: Fundus Photography (FP) measure: Optos measure: Autofluorescence (AF) measure: Optical Coherence Tomography (OCT) measure: Full-Field Electroretinogram (ff-ERG) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Tuebingen city: Tuebingen state: Baden-Wuerttemberg zip: 72076 country: Germany lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06368362 id: CBM-I001 briefTitle: Cognitive Bias Modification for Interpretation Individuals With Chronic Musculoskeletal Pain overallStatus: COMPLETED date: 2020-11-17 date: 2021-05-01 date: 2021-05-01 date: 2024-04-16 date: 2024-04-16 name: University of Southampton class: OTHER name: Economic and Social Research Council, United Kingdom briefSummary: Cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign, rather than interpret it as being related to pain. The goal of this randomised controlled trial was to explore the feasibility and potential clinical benefits of CBM-I in people with chronic pain and also healthy, pain-free individuals. conditions: Chronic Pain conditions: Musculoskeletal Pain Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups of participants (chronic musculoskeletal pain, healthy) were recruited, and within each group participants were randomised to one of two experimental conditions with a 1:1 allocation ratio with a parallel design. Participants with chronic musculoskeletal pain were randomised to benign CBM-I or no CBM-I, and healthy participants were randomised to benign CBM-I or pain-related CBM-I. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants are not informed of the conditioned they are randomised to in this psychological intervention. whoMasked: PARTICIPANT count: 84 type: ACTUAL name: Benign cognitive bias modification for interpretation name: Pain-related cognitive bias modification for interpretation measure: Emotional response to exercise induced pain measure: Emotional response to pain-related images measure: Fear of Pain measure: Anxiety measure: Depression measure: Emotional response to average clinical pain measure: Pain severity measure: Pain interference measure: Pain-related interpretation bias index sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Southampton city: Southampton state: Hampshire zip: SO17 1BJ country: United Kingdom lat: 50.90395 lon: -1.40428 hasResults: False
nctId: NCT06368349 id: 202101771B0 briefTitle: Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma overallStatus: COMPLETED date: 2022-03-01 date: 2023-06-21 date: 2023-06-30 date: 2024-04-16 date: 2024-04-18 name: Chang Gung Memorial Hospital class: OTHER briefSummary: A total of 145 Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) were retrospectively enrolled at Kaohsiung Chang Gung Memorial Hospital between 2006 and 2019. Clinical records from 7 days before LT (pre-LT) to 1 year after LT (post-LT) were analysed. In a prospective study from March 2022 to June 2023, 20 lymphopenia and 25 non-lymphopenia HCC recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry. conditions: Lymphopenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 190 type: ACTUAL measure: Persistent lymphopenia predict poor overall survival measure: T cell and its subtype were mainly decrease in pre-LT lymphopenia population of HCC patient measure: Long-term peri-LT lymphopenia HCC recipients is associated with increased sirolimus use and decreased tacrolimus use sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery city: Kaohsiung zip: 833 country: Taiwan lat: 22.61626 lon: 120.31333 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2021-10-20 uploadDate: 2024-04-11T03:02 filename: Prot_SAP_000.pdf size: 422513 hasResults: False
nctId: NCT06368336 id: 994894 briefTitle: Health Related Quality of Life After Intensive Care for Sepsis, a National Cohort Study. overallStatus: COMPLETED date: 2008-01-01 date: 2022-04-01 date: 2022-12-31 date: 2024-04-16 date: 2024-04-17 name: Uppsala University Hospital class: OTHER name: Sepsisfonden briefSummary: The study aims to map the health-related quality of life (HRQoL) after intensive care for Sepsis with the hypothesis that it will be lower than that in the general population. The investigators also want to identify factors that are associated with low HRQoL, to see if those are available for interventions from the health care system and society to improve quality of life after treatment for sepsis in the intensive care unit (ICU). conditions: Sepsis conditions: Septic Shock conditions: Sepsis, Severe studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 210484 type: ACTUAL measure: Health-related Quality of Life after ICU (intensive care unit) treatment with/for sepsis measure: Ability to work before and after ICU (intensive care unit) treatment for Sepsis measure: The burden of disease at ICU (intensive care unit) admittance and after ICU treatment for Sepsis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06368323 id: H-01-24-9931 briefTitle: Effect of Community Choir Singing in People With Chronic Post-stroke Aphasia overallStatus: RECRUITING date: 2024-04-22 date: 2025-12-31 date: 2025-12-31 date: 2024-04-16 date: 2024-04-22 name: University of Ottawa class: OTHER name: Toronto Metropolitan University name: Université de Montréal name: Université du Québec à Trois-Rivières name: University of South Florida briefSummary: The goal of this randomized controled trial is to test the effects of assigning people with chronic post-stroke aphasia to 12 weekly choir sessions, compared to usual care.
12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master, and home singing training (3 x 30-minutes-sessions/week, total 18h) conditions: Aphasia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A parallel group randomized trial design with a secondary crossover extension primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Outcomes will be measured by blinded assessors where possible, using blinded video or audio recordings. whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Choir singing name: Usual care measure: Communication Index measure: Level of confidence in communication measure: Aphasia severity index measure: Speech and language in functional communication measure: Apraxia of speech severity measure: Health related quality of life assessed by the the Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39) measure: Emotional wellbeing measure: Social participation measure: Generic measure of health measure: Appetence to music measure: Singing voice abilities measure: Voice - Pitch measure: Voice - Maximum Phonation Time measure: Voice - Dynamic range measure: Mood measure: Biosocial indexes measure: Expectations on a 100-scale measure: Satisfaction on a 100-scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of South Florida status: NOT_YET_RECRUITING city: Tampa state: Florida zip: 33620 country: United States name: Jennifer Bugos, Ph.D. role: CONTACT email: bugosj@usf.edu lat: 27.94752 lon: -82.45843 facility: University of Ottawa status: RECRUITING city: Ottawa state: Ontario zip: K1N 6N5 country: Canada name: Anna Zumbansen, PhD role: CONTACT phone: 613-562-5800 phoneExt: 8393 email: azumbans@uottawa.ca name: Narges Bayat, Master role: CONTACT phone: 613-562-5800 phoneExt: 8393 email: nbaya063@uottawa.ca lat: 45.41117 lon: -75.69812 facility: Toronto Metropolitan University status: NOT_YET_RECRUITING city: Toronto state: Ontario zip: M5B 0C3 country: Canada name: Arla Good, Ph.D. role: CONTACT email: arla.good@torontomu.ca lat: 43.70011 lon: -79.4163 facility: Université de Montréal status: NOT_YET_RECRUITING city: Montréal state: Quebec zip: H3C 3J7 country: Canada name: Carole Anglade, Ph.D. role: CONTACT email: carole.anglade@umontreal.ca lat: 45.50884 lon: -73.58781 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-04-16 uploadDate: 2024-04-10T11:45 filename: ICF_000.pdf size: 129388 hasResults: False
nctId: NCT06368310 id: R124807 id: 23/WM/0166 type: OTHER domain: NHS Research Ethics Committee Reference briefTitle: FIH Clinical Investigation of Graphene Electrodes for Brain Mapping overallStatus: NOT_YET_RECRUITING date: 2024-05-28 date: 2025-01-31 date: 2025-01-31 date: 2024-04-16 date: 2024-04-16 name: University of Manchester class: OTHER name: Northern Care Alliance NHS Foundation Trust name: European Commission name: Inbrain Neuroelectronics briefSummary: The goal of this clinical investigation of a medical device is to test the safety of graphene based electrodes when used during surgery for resection of brain tumors. The main questions that it aims to answer are:
Participants will undergo tumor surgery as usual with the study electrodes being tested alongside a standard monitoring system. If they are awake for part of their surgery they may be asked to complete specific tasks such as naming objects from a list modified for the study. They will be monitored subsequently for any complications including undergoing an additional MRI scan 6 weeks after their surgery. conditions: Brain Tumor conditions: Glioma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 8 type: ESTIMATED name: INBRAIN Graphene Cortical Interface measure: To evaluate the preliminary safety of the investigational device for its intended use measure: Assess the ability of the device to record signals from the brain measure: Evaluate the ability of the device to provide functional stimulation of the brain measure: Assess stability of sensing and stimulating electrodes measure: Evaluate device usability - an assessment by questionnaire of the operating surgeon's impression of the suitability of the device for sensing and stimulation during brain tumor surgery measure: Assess the quality of the recorded somatosensory evoked potentials (SEPs) - sensing part A (exploratory) measure: Assess the quality of the recorded baseline brain activity - sensing part B (exploratory) measure: Assess the ability of detecting brain evoked responses during stimulation of the brain (exploratory) measure: Evaluate decoding capability from data recorded during language task (exploratory) measure: Evaluate signal characteristics of tumour infiltrated brain regions (exploratory) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust city: Salford state: Greater Manchester zip: M6 8HD country: United Kingdom name: Hannah Howlett role: CONTACT email: RDResearch@nca.nhs.uk name: David J Coope, PhD FRCS role: PRINCIPAL_INVESTIGATOR lat: 53.48771 lon: -2.29042 hasResults: False
nctId: NCT06368297 id: BSERE22-APP007-FED briefTitle: The Effect of Ketone Ester Supplementation and Ketogenic Diet on Brain Plasticity in Overweight/Obese Adults overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-08 date: 2024-04-16 date: 2024-04-16 name: University of Macau class: OTHER briefSummary: This project comprises an initial crossover placebo-controlled neurophysiological study to ascertain the effect of acute ketone ester ingestion on motor cortex plasticity, followed by a second 2-week intervention study aimed to compare the effect of a ketogenic diet versus ketone ester supplementation on motor cortex plasticity, resting brain function and structure, and metabolic and neuroendocrine responses. conditions: Overweight and Obesity conditions: Cognitive Change conditions: Psychophysiologic Reaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Ketone Monoester Supplementation name: Ketogenic diet measure: Brain Plasticity measure: Grey Matter Volume measure: Cortical Thickness measure: Blood-Oxygen-Level-Dependent (BOLD) Signal Changes measure: Blood Glucose measure: Blood Beta-Hydroxybutyrate measure: Blood Insulin measure: Leptin measure: Ghrelin measure: Brain-Derived Neurotrophic Factor measure: Reaction Time of Attention Network Test measure: Accuracy of Attention Network Test measure: Reaction Time of Stroop Task measure: Accuracy of Stroop Task measure: Reaction Time of N-back Task measure: Accuracy of N-back Task measure: Cerebral Hemoglobin Concentration measure: Height in Kilograms measure: Weight in Meters measure: Body Fat Percentage measure: Fat Mass measure: Muscle Mass measure: Body Water measure: Body Mass Index measure: Skinfold Thickness measure: Maximal Oxygen Uptake sex: ALL minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT hasResults: False